U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 215503
Company: HIKMA

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
LIRAGLUTIDE LIRAGLUTIDE 18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription AP No No

Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
12/23/2024 ORIG-1 Approval STANDARD Letter (PDF)
Review (PDF)

Label is not available on this site.

 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215503Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215503Orig1s000edt.pdf

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS; 18MG/3ML (6MG/ML)
TE Code = AP

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
LIRAGLUTIDE LIRAGLUTIDE 18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription No AP 215503 HIKMA
LIRAGLUTIDE LIRAGLUTIDE 18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription No AP 218115 NANJING KING-FRIEND
VICTOZA LIRAGLUTIDE 18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription Yes AP 022341 NOVO NORDISK INC
Back to Top